These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
354 related items for PubMed ID: 31287015
1. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Giancane G, Muratore V, Marzetti V, Quilis N, Benavente BS, Bagnasco F, Alongi A, Civino A, Quartulli L, Consolaro A, Ravelli A. Arthritis Res Ther; 2019 Jul 08; 21(1):168. PubMed ID: 31287015 [Abstract] [Full Text] [Related]
2. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. Bava C, Mongelli F, Pistorio A, Bertamino M, Bracciolini G, Dalprà S, Davì S, Lanni S, Muratore V, Pederzoli S, Rosina S, Schiappapietra B, Suffia C, Varnier G, Verazza S, Giancane G, Consolaro A, Ravelli A. Pediatr Rheumatol Online J; 2019 Jul 25; 17(1):50. PubMed ID: 31345226 [Abstract] [Full Text] [Related]
4. Cumulative Damage in Juvenile Idiopathic Arthritis: A Multicenter Study From the Pediatric Rheumatology Arab Group. Al-Mayouf SM, Hashad S, Khawaja K, Alrasheedi A, Abdwani R, Abushhaiwia A, AlSuwaiti M, Alzyoud R, Al Abrawi S, Asiri A, Alshaikh M, Sharif E, Muzaffer M, Alsewairi W, Zlenti M, Kawaja E, Almutairi M, Majeed M, Lotfy H, AlMarri M, Almutairi N, Pediatric Arab Rheumatology Group. Arthritis Care Res (Hoboken); 2021 Apr 25; 73(4):586-592. PubMed ID: 32886859 [Abstract] [Full Text] [Related]
5. Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment. Nalbanti P, Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Farmaki E, Bamidis P, Papachristou F. Rheumatol Int; 2018 Jul 25; 38(7):1241-1250. PubMed ID: 29845429 [Abstract] [Full Text] [Related]
7. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period. Vilaiyuk S, Soponkanaporn S, Jaovisidha S, Benjaponpitak S, Manuyakorn W. Int J Rheum Dis; 2016 Dec 25; 19(12):1342-1350. PubMed ID: 26176300 [Abstract] [Full Text] [Related]
8. Progression of articular and extraarticular damage in oligoarticular juvenile idiopathic arthritis. de Oliveira Sato J, Corrente JE, Saad Magalhães C. Clin Exp Rheumatol; 2011 Dec 25; 29(5):871-7. PubMed ID: 21962036 [Abstract] [Full Text] [Related]
9. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis. McMahan R, Balfe LM, Greene L. J Manag Care Pharm; 2012 Dec 25; 18(1 Suppl B):1-16. PubMed ID: 22376227 [Abstract] [Full Text] [Related]
10. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients? Polat MC, Çelikel E, Tekin ZE, Kurt T, Kaplan MM, Güngörer V, Tekgöz N, Sezer M, Karagöl C, Coşkun S, Öner N, Sezer S, Acar BÇ. Eur J Pediatr; 2024 Jun 25; 183(6):2725-2731. PubMed ID: 38554171 [Abstract] [Full Text] [Related]
12. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, Scuccimarri R, Berard R, Tse SM, Morishita K, Stringer E, Johnson N, Levy DM, Duffy KW, Cabral DA, Rosenberg AM, Larché M, Dancey P, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille AL, Haddad E, Houghton K, Spiegel L, Turvey SE, Schmeling H, Lang B, Ellsworth J, Ramsey S, Bruns A, Campillo S, Benseler S, Chédeville G, Schneider R, Yeung R, Duffy CM, ReACCh-Out investigators. Ann Rheum Dis; 2015 Oct 25; 74(10):1854-60. PubMed ID: 24842571 [Abstract] [Full Text] [Related]
13. Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis. Pohjankoski H, Kautiainen H, Lauri JV, Puolakka K, Rantalaiho V. Clin Rheumatol; 2020 Jan 25; 39(1):263-268. PubMed ID: 31346886 [Abstract] [Full Text] [Related]
17. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis. Funk RS, Chan MA, Becker ML. Pharmacotherapy; 2017 Jun 25; 37(6):700-711. PubMed ID: 28475276 [Abstract] [Full Text] [Related]
18. Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs. Ozer Y, Yildiz M, Turan H, Tarcin G, Bingol Aydin D, Gunalp A, Haslak F, Kilic Konte E, Aslan E, Koker O, Bayramoglu E, Sahin S, Adrovic A, Barut K, Kasapcopur O, Evliyaoglu O. Clin Rheumatol; 2024 Jan 25; 43(1):399-406. PubMed ID: 37646858 [Abstract] [Full Text] [Related]
19. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Mourão AF, Santos MJ, Melo Gomes JA, Martins FM, Mendonça SC, Oliveira Ramos F, Fernandes S, Salgado M, Guedes M, Carvalho S, Costa JA, Brito I, Duarte C, Furtado C, Lopes A, Rodrigues A, Sequeira G, Branco JC, Fonseca JE, Canhão H. Rheumatology (Oxford); 2016 Apr 25; 55(4):697-703. PubMed ID: 26672905 [Abstract] [Full Text] [Related]
20. The use of methotrexate in children with rheumatic diseases. Gutiérrez-Suárez R, Burgos-Vargas R. Clin Exp Rheumatol; 2010 Apr 25; 28(5 Suppl 61):S122-7. PubMed ID: 21044445 [Abstract] [Full Text] [Related] Page: [Next] [New Search]